|
시장보고서
상품코드
1941471
백신 보조제 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 투여별, 지역별, 지역별, 부문별 예측(2026-2033년)Vaccine Adjuvants Market Size, Share & Trends Analysis Report By Type, By Application, By Administration, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
백신 보조제 시장 요약
세계의 백신 보조제 시장 규모는 2025년에 39억 4,000만 달러로 추정되며, 2033년까지 59억 6,000만 달러에 달할 것으로 예측됩니다.
2026-2033년 연평균 복합 성장률(CAGR) 5.60%를 나타낼 것으로 예측됩니다. 이 시장의 성장은 신종 및 재유행성 전염병에 대한 효과적인 백신에 대한 수요 증가와 암과 같은 만성질환의 유병률 증가에 따라 주도되고 있습니다.
면역 반응의 효과, 지속성 및 폭을 강화하는 보조제의 역할에 대한 인식이 높아짐에 따라 예방 백신과 치료 백신 모두에서 보조제의 채택이 증가하고 있습니다. 면역학 및 분자생물학의 발전으로 사포닌계 보조제, Toll-like receptor(TLR) 작용제 등 차세대 보조제 개발이 가능해졌습니다. 이들은 면역 경로를 선택적으로 표적화하여 안전성 및 유효성 프로파일을 개선합니다. 이러한 혁신은 항원 투여량을 줄이면서 강력한 면역 반응을 유도할 수 있는 백신의 미충족 수요를 충족시키고, 비용 효율성과 확장성을 향상시킬 수 있습니다. 예를 들어 2025년 8월 Springer Nature사가 『Medicinal Chemistry Research』(제34권, 1817-1832페이지)에 게재한 리뷰에 따르면 널리 연구되고 있는 사포닌 보조제 QS-21이 약 65%의 QS-21-Api와 35%의 QS-21-xylene 이성질체로 구성되어 있음을 밝혀냈습니다. 의 QS-21-자일렌 이성질체로 구성되어 있음을 밝혀냈습니다. 저자들은 이 화합물의 생합성 해명에 성공했다고 보고하고, 반합성에 의한 수율을 비교하고 있습니다. 특히 유전자 재조합 효모를 이용한 생산에서는 중량 대비 약 0.0012%, 천연 유래에서는 약 0.0032%이며, 항원 특이적 항체 및 세포성 면역 반응의 증강에 있으며, 그 역할을 강조하고 있습니다.
또한 정부, 비정부기구, 제약기업의 백신 연구개발에 대한 투자 증가가 시장 성장을 가속화하고 있습니다. 첨단화된 보조제 첨가 백신의 보급 확대, 특히 중저소득 국가를 대상으로 한 전 세계적인 노력이 중심적인 역할을 하고 있습니다. 예를 들어 2024년 6월 백신연합 Gavi는 새로운 5개년 전략 'Gavi 6.0'을 승인하고, 2026-2030년 5억 명 이상의 아동 및 청소년 추가 예방접종 지원, 800만-900만 명의 사망 예방(이 중 150만 명은 HPV 백신으로 인한 사망), 20개 이상의 질병에 대한 백신 접근성 확대 등을 약속했습니다. 20개 이상의 질병을 대상으로 한 백신 접근성 확대가 약속되었습니다. 특히 뎅기열 등 기후에 민감한 질병과 전략주기 종료 시점에 도입이 예정된 신종 결핵 백신에 대한 중점적인 노력이 추가되었습니다. 이러한 노력은 COVID-19 및 기타 감염병 발생 이후 강화된 팬데믹 대응과 함께 신속한 개발 및 배포가 가능한 보조제 강화 백신의 필요성이 더욱 커지고 있습니다.
시장은 또한 신속한 승인 절차 및 핵심 백신 기술에 대한 집중적인 자금 지원과 같은 유리한 규제 지원의 혜택을 누리고 있습니다. 그러나 높은 개발 비용, 엄격한 규제 요건, 광범위한 임상 검증의 필요성 등은 여전히 주요 장벽으로 작용하고 있습니다. 이러한 제약에도 불구하고 보조제 기반 백신 개발 파이프라인의 확대와 공중보건에서 예방접종의 역할에 대한 전 세계적인 인식이 높아짐에 따라 백신 보조제 산업은 예측 기간 중 지속적인 성장을 보일 것으로 예측됩니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 백신 보조제 시장 변수, 동향, 범위
제4장 백신 보조제 : 유형별 추정·동향 분석
제5장 백신 보조제 : 용도별 추정·동향 분석
제6장 백신 보조제 : 투여별 추정·동향 분석
제7장 백신 보조제 시장 : 지역별 추정·동향 분석
제8장 경쟁 구도
KSA 26.03.12Vaccine Adjuvants Market Summary
The global vaccine adjuvants market size was estimated at USD 3.94 billion in 2025 and is projected to reach USD 5.96 billion by 2033, growing at a CAGR of 5.60% from 2026 to 2033. The growth of the market is driven by the increasing demand for effective vaccines to combat emerging and re-emerging infectious diseases, as well as the rising prevalence of chronic conditions such as cancer.
The growing recognition of adjuvants' role in enhancing the efficacy, durability, and breadth of immune responses is propelling their adoption across both prophylactic and therapeutic vaccines. Advancements in immunology and molecular biology have enabled the development of next-generation adjuvants, including saponin-based adjuvants and toll-like receptor (TLR) agonists, which selectively target immune pathways and deliver improved safety and efficacy profiles. These innovations address the unmet need for vaccines capable of eliciting strong immune responses with reduced antigen doses, improving cost efficiency and scalability. For instance, in August 2025, Springer Nature published a review in Medicinal Chemistry Research (Volume 34, pages 1817-1832) highlighting that the widely studied saponin adjuvant QS-21 consists of approximately 65 percent QS-21-Api and 35 percent QS-21-Xyl isomers and has been incorporated into licensed vaccines such as Shingrix, Mosquirix, and Arexvy, with the authors reporting successful biosynthetic elucidation and comparing semi-synthetic yields, including engineered yeast production at roughly 0.0012 percent weight-by-weight versus about 0.0032 percent from natural sources, underscoring its role in enhancing antigen-specific antibody and cellular immune responses.
In addition, rising investments in vaccine research and development by governments, non-governmental organizations, and pharmaceutical companies are accelerating market growth. Global initiatives are playing a central role in expanding access to advanced adjuvanted vaccines, particularly in low- and middle-income countries. For instance, in June 2024, Gavi, the Vaccine Alliance approved its new five-year strategy, Gavi 6.0, committing to support countries in vaccinating more than 500 million additional children and adolescents, projecting the prevention of 8-9 million deaths, including 1.5 million through HPV vaccination, and expanding access to vaccines targeting 20+ diseases during the 2026-2030 period, with an added focus on climate-sensitive diseases such as dengue and the anticipated rollout of a new tuberculosis vaccine by the end of the strategy cycle. These initiatives, alongside heightened pandemic preparedness following COVID-19 and other outbreaks, have reinforced the need for adjuvant-enhanced vaccines that enable rapid development and deployment.
The market also benefits from favorable regulatory support, including expedited approval pathways and targeted funding for critical vaccine technologies. However, challenges such as high development costs, stringent regulatory requirements, and the need for extensive clinical validation remain key barriers. Despite these constraints, the expanding pipeline of adjuvant-based vaccines and growing global awareness of immunization's role in public health continue to position the vaccine adjuvants industry for sustained growth over the forecast period.
Global Vaccine Adjuvants Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global vaccine adjuvants market report based on type, application, administration, and region:
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Pathogen
- Adjuvant emulsion
- Particulate
- Combination
- Others
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Infectious diseases
- Cancer
- Others
- Administration Outlook (Revenue, USD Million, 2021 - 2033)
- Oral
- Intradermal
- Intranasal
- Intramuscular
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Type
- 1.1.2. Application
- 1.1.3. Administration
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline.
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database.
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. Application outlook
- 2.2.3. Administration outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Vaccine Adjuvants Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. Vaccine Adjuvants Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
- 3.4.1. Industry Analysis - Porter's
Chapter 4. Vaccine Adjuvants: Type Estimates & Trend Analysis
- 4.1. Vaccine Adjuvants Market: Key Takeaways
- 4.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2025 & 2033
- 4.3. Pathogen
- 4.3.1. Pathogen market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.4. Adjuvant emulsion
- 4.4.1. Adjuvant emulsion market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.5. Particulate
- 4.5.1. Particulate market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6. Combination
- 4.6.1. Combination market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.7. Others
- 4.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 5. Vaccine Adjuvants: Application Estimates & Trend Analysis
- 5.1. Vaccine Adjuvants Market: Key Takeaways
- 5.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2025 & 2033
- 5.3. Infectious diseases
- 5.3.1. Infectious diseases market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.4. Cancer
- 5.4.1. Cancer market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.5. Others
- 5.5.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 6. Vaccine Adjuvants: Administration Estimates & Trend Analysis
- 6.1. Vaccine Adjuvants Market: Key Takeaways
- 6.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2025 & 2033
- 6.3. Oral
- 6.3.1. Oral market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.4. Intradermal
- 6.4.1. Intradermal market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.5. Intranasal
- 6.5.1. Intranasal market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.6. Intramuscular
- 6.6.1. Intramuscular market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.7. Others
- 6.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 7. Vaccine Adjuvants Market: Regional Estimates & Trend Analysis
- 7.1. Regional Outlook
- 7.2. Vaccine Adjuvants Market by Region: Key Takeaways
- 7.3. North America
- 7.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.3.3. Canada
- 7.3.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.3.4. Mexico
- 7.3.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.2. Germany
- 7.4.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.3. France
- 7.4.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.4. Italy
- 7.4.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.5. Spain
- 7.4.5.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.6. Denmark
- 7.4.6.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.7. Sweden
- 7.4.7.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.8. Norway
- 7.4.8.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.1. UK
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.2. China
- 7.5.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.3. India
- 7.5.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.4. Australia
- 7.5.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.5. Thailand
- 7.5.5.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.6. South Korea
- 7.5.6.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.1. Japan
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.6.2. Argentina
- 7.6.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.6.1. Brazil
- 7.7. MEA
- 7.7.1. South Africa
- 7.7.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.7.2. Saudi Arabia
- 7.7.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.7.3. UAE
- 7.7.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.7.4. Kuwait
- 7.7.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.7.1. South Africa
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Market Participant Categorization
- 8.2.1. GlaxoSmithKline plc
- 8.2.1.1. Company overview
- 8.2.1.2. Financial performance
- 8.2.1.3. Product benchmarking
- 8.2.1.4. Strategic initiatives
- 8.2.2. Novartis/CSL Limited
- 8.2.2.1. Company overview
- 8.2.2.2. Financial performance
- 8.2.2.3. Product benchmarking
- 8.2.2.4. Strategic initiatives
- 8.2.3. Agenus Inc
- 8.2.3.1. Company overview
- 8.2.3.2. Financial performance
- 8.2.3.3. Product benchmarking
- 8.2.3.4. Strategic initiatives
- 8.2.4. Adjuvance Technologies, Inc
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Product benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. Novavax Inc.
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Product benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. SPI Pharma
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Product benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. Invivogen
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Product benchmarking
- 8.2.7.4. Strategic initiatives
- 8.2.8. Avanti Polar Lipids
- 8.2.8.1. Company overview
- 8.2.8.2. Financial performance
- 8.2.8.3. Product benchmarking
- 8.2.8.4. Strategic initiatives
- 8.2.9. Brentagg
- 8.2.9.1. Company overview
- 8.2.9.2. Financial performance
- 8.2.9.3. Product benchmarking
- 8.2.9.4. Strategic initiatives
- 8.2.1. GlaxoSmithKline plc
